Scientific Advances in Lung Cancer 2015

Tsao, Anne S.; Scagliotti, Giorgio Vittorio; Bunn, Paul A.; Carbone, David P.; Warren, Graham; Bai, Chunxue; Koning, Harry J. de; Yousaf-Khan, A.U.; McWilliams, Annette; Tsao, Ming Sound; Adusumilli, Prasad S.; Rami‐Porta, Ramón; Asamura, Hisao; Schil, Paul Van; Darling, Gail; Ramalingam, Suresh S.; Gomez, Daniel R.; Rosenzweig, Kenneth E.; Zimmermann, Stefan; Peters, Solange; Ou, Sai Hong Ignatius; Reungwetwattana, Thanyanan; Jänne, Pasi A.; Mok, Tony; Wakelee, Heather A.; Pirker, Robert; Mazières, Julien; Brahmer, Julie R.; Zhou, Yang; Herbst, Roy S.; Papadimitrakopoulou, Vassiliki A.; Redman, Mary W.; Wynes, Murry W.; Gandara, David R.; Kelly, Ronan J.; Hirsch, Fred R.; Pass, Harvey I.

doi:10.1016/j.jtho.2016.03.012

Cited by 254 publications

(195 citation statements)

References 232 publications

(225 reference statements)

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…Once tumors had reached a measurable size of 17 mm, the tumors were harvested from the animals. Then, tumors were excised from donor animals, placed in sterile physiological saline containing antibiotics and cut into small fragments of approximately 2 mm 3 . Under brief diethyl ether anesthesia, a single fragment was implanted subcutaneously into the flank of each mouse using a trocar.…”

Section: In Vivo Antitumoral Assaymentioning

confidence: 99%

“…Serial caliper measurements of perpendicular diameters were used to calculate tumor volume. Data are plotted as mean relative tumor volume (mm 3 ). The mean time to reach Relative Tumor Volume (RTV) of 4 for vehicle-treated control group was 5 days whereas for TPTQ treated (800 mg/kg) group was 10 days.…”

Section: In Vivo Antitumor Activity Of Tptqmentioning

confidence: 99%

“…1 There were 1.82 and 1.59 million new lung cancer cases and deaths worldwide, respectively. 2,3 However, significant progress is underway in both the prevention and treatment of lung cancer. 3 The development of new therapeutic approach to breast cancer remains one of the most challenging area in cancer research.…”

Section: Introductionmentioning

confidence: 99%

“…2,3 However, significant progress is underway in both the prevention and treatment of lung cancer. 3 The development of new therapeutic approach to breast cancer remains one of the most challenging area in cancer research. Many tropical plants have interesting biological activities with potential therapeutic applications.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

In vivo study of tetraprenyltoluquinone, an anticancer compounds from Garcinia cowa Roxb

Wahyuni¹,

Hui²,

Stanslas³

et al. 2017

JYP

View full text Add to dashboard Cite

Objective: To investigate the in vivo antitumor effect of TPTQ against H-460 lung cancer cell lines in nude mice. Materials and Methods: Female nude mice bearing H-460 tumor at size approximately 5 mm in diameter were treated with a single intraperitoneal dose 800 mg/kg of TPTQ. The vehicletreated (10% tween 80) animals were used as control group. The tumor size and mice body weight were measured for 14 days. Results: Single treatment of 800 mg/kg of TPTQ displayed moderate antitumor activity against H-460 tumor xenografts as compared with vehicle-treated control. The mean time to reach RTV of 4 for vehicle-treated control group was 4.5 days whereas for TPTQ-treated (800 mg/kg) group was 9.5 days. Conclusion:The results showed that TPTQ slowed the tumor growth by 5 days. Thus, TPTQ may be considered as a promising compound in cancer chemotherapy.

show abstract

Section: In Vivo Antitumoral Assaymentioning

confidence: 99%

Section: In Vivo Antitumor Activity Of Tptqmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In vivo study of tetraprenyltoluquinone, an anticancer compounds from Garcinia cowa Roxb

Wahyuni¹,

Hui²,

Stanslas³

et al. 2017

JYP

View full text Add to dashboard Cite

show abstract

“…ALK (anaplastic lymphoma kinase) rearrangements are the driver mutation in 3–7% of NSCLC [1] with EML4 (echinoderm microtubule-associated protein-like 4) as the most common fusion partner. Soda et al were the first to demonstrate that EML4-ALK fusion was a distinct oncogenic event in a subset of NSCLC [2].…”

Section: Introductionmentioning

confidence: 99%

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Qin

Gadgeel

2017

Targ Oncol

View full text Add to dashboard Cite

Tumorigenic rearrangements in anaplastic lymphoma kinase (ALK) account for 3–7% of all non-small cell lung cancers (NSCLC). Treatment with targeted tyrosine kinase inhibitors (TKIs) has shown impressive clinical responses. Crizotinib was the first agent approved for front-line therapy of ALK-rearranged NSCLC after it demonstrated superiority to chemotherapy in response rate, duration of response, and progression-free survival. However, eventually all patients progress on crizotinib therapy, with the central nervous system (CNS) being the most common site, which served as the impetus for the development of more potent next-generation ALK inhibitors. Currently, ceritinib, alectinib, and brigatinib are all approved for second-line therapy after progression on or intolerance to crizotinib. Investigations into whether the initiation of a second-generation ALK inhibitor as first-line therapy is the superior treatment paradigm has resulted in the approval of ceritinib as initial therapy. Alectinib has also shown impressive results as front-line therapy, as recently reported in two large randomized studies that compared it to crizotinib. There is a significant need to better understand the drivers of and mechanisms underlying resistance to ALK inhibitors. While specific mutations have been identified, there is currently only limited evidence that the identification of specific mutations should impact selection of the next ALK inhibitor. The best treatment option for patients who become TKI refractory is also unclear, though there is some evidence to suggests that these patients are not responsive to checkpoint inhibitors and may respond better to chemotherapy. Combination therapy with other classes of agents may help to overcome resistance mechanisms and should be investigated further.

show abstract

Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol

Zhu

Zhang

Cai

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Scientific Advances in Lung Cancer 2015

Cited by 254 publications

References 232 publications

In vivo study of tetraprenyltoluquinone, an anticancer compounds from Garcinia cowa Roxb

In vivo study of tetraprenyltoluquinone, an anticancer compounds from Garcinia cowa Roxb

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol

Contact Info

Product

Resources

About